From intravenous to subcutaneous pertuzumab/trastuzumab in breast cancer: Clinical and pharmacoeconomic drivers and barriers to switching. - Gaudio M; Floreani A; Schivardi G; Alaimo D; Basilico V; Lorenzetti I; Crepaldi C; Tinterri B; Panzardi A; Strada D; Saltalamacchia G; Jacobs F; et al. (Tumori, 2026)